Patents Assigned to SARcode Bioscience Inc.
-
Publication number: 20200087287Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.Type: ApplicationFiled: May 14, 2019Publication date: March 19, 2020Applicant: SARcode Bioscience Inc.Inventor: John BURNIER
-
Publication number: 20200009130Abstract: The present invention provides lifitegrast formulations useful for the treatment of immune-related diseases of the ocular surface. The formulations and methods provided herein are particularly useful for treatment of ocular anterior segment tissues.Type: ApplicationFiled: December 15, 2017Publication date: January 9, 2020Applicant: SARcode Bioscience Inc.Inventors: Jou-Ku CHUNG, Elizabeth SPENCER, Matthew HUNT, Devin WELTY, Thomas MCCAULEY
-
Publication number: 20190382389Abstract: Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.Type: ApplicationFiled: January 15, 2019Publication date: December 19, 2019Applicant: SARcode Bioscience Inc.Inventors: James Robert Zeller, Sripathy Venkatraman, Elisabeth C.A. Brot, Subashree Iyer, Michael Hall
-
Publication number: 20190300485Abstract: The present invention is related to a two-step carboxylation reaction of an aryl group using continuous flow reaction conditions. This process permits large scale synthesis of useful reaction products in high yield.Type: ApplicationFiled: April 9, 2019Publication date: October 3, 2019Applicant: SARCODE BIOSCIENCE INC.Inventors: Scott Tweedie, Sripathy Venkatraman, James Zeller
-
Publication number: 20190134022Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).Type: ApplicationFiled: October 26, 2018Publication date: May 9, 2019Applicant: SARcode Bioscience Inc.Inventors: Wang SHEN, Kenneth BARR, Johan D. OSLOB, Min ZHONG
-
Patent number: 10273212Abstract: The present invention is related to a two-step carboxylation reaction of an aryl group using continuous flow reaction conditions. This process permits large scale synthesis of useful reaction products in high yield.Type: GrantFiled: June 28, 2017Date of Patent: April 30, 2019Assignee: SARCODE BIOSCIENCE INC.Inventors: Scott Tweedie, Sripathy Venkatraman, James Zeller
-
Patent number: 10214517Abstract: Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.Type: GrantFiled: June 13, 2017Date of Patent: February 26, 2019Assignee: SARCODE BIOSCIENCE INC.Inventors: James Robert Zeller, Sripathy Venkatraman, Elisabeth C. A. Brot, Subashree Iyer, Michael Hall
-
Patent number: 10188641Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.Type: GrantFiled: October 3, 2013Date of Patent: January 29, 2019Assignee: SARCODE BIOSCIENCE INC.Inventors: Thomas Gadek, John Burnier
-
Patent number: 10124000Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).Type: GrantFiled: November 12, 2015Date of Patent: November 13, 2018Assignee: SARCODE BIOSCIENCE INC.Inventors: Wang Shen, Kenneth Barr, Johan D. Oslob, Min Zhong
-
Publication number: 20180251452Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.Type: ApplicationFiled: January 29, 2018Publication date: September 6, 2018Applicant: SARcode Bioscience Inc.Inventor: John BURNIER
-
Publication number: 20180118726Abstract: Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.Type: ApplicationFiled: June 13, 2017Publication date: May 3, 2018Applicant: SARcode Bioscience Inc.Inventors: James Robert ZELLER, Sripathy VENKATRAMAN, Elisabeth C. A. BROT, Subashree IYER, Michael HALL
-
Publication number: 20180118689Abstract: The present invention is related to a two-step carboxylation reaction of an aryl group using continuous flow reaction conditions. This process permits large scale synthesis of useful reaction products in high yield.Type: ApplicationFiled: June 28, 2017Publication date: May 3, 2018Applicant: SARCODE BIOSCIENCE INC.Inventors: Scott Tweedie, Sripathy Venkatraman, James Zeller
-
Patent number: 9890141Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.Type: GrantFiled: May 3, 2016Date of Patent: February 13, 2018Assignee: SARCODE BIOSCIENCE INC.Inventor: John Burnier
-
Patent number: 9708303Abstract: Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.Type: GrantFiled: June 23, 2015Date of Patent: July 18, 2017Assignee: SARCODE BIOSCIENCE INC.Inventors: James Robert Zeller, Sripathy Venkatraman, Elisabeth C. A. Brot, Subashree Iyer, Michael Hall
-
Publication number: 20170143693Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.Type: ApplicationFiled: December 9, 2016Publication date: May 25, 2017Applicant: SARCODE BIOSCIENCE INC.Inventors: Thomas GADEK, John BURNIER
-
Publication number: 20170143690Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.Type: ApplicationFiled: November 21, 2016Publication date: May 25, 2017Applicant: SARCODE BIOSCIENCE INC.Inventors: Thomas GADEK, John BURNIER
-
Publication number: 20170143692Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.Type: ApplicationFiled: December 8, 2016Publication date: May 25, 2017Applicant: SARCODE BIOSCIENCE INC.Inventors: Thomas GADEK, John BURNIER
-
Publication number: 20170143691Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.Type: ApplicationFiled: November 30, 2016Publication date: May 25, 2017Applicant: SARCODE BIOSCIENCE INC.Inventors: Thomas GADEK, John BURNIER
-
Publication number: 20170029410Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.Type: ApplicationFiled: May 3, 2016Publication date: February 2, 2017Applicant: SARcode Bioscience Inc.Inventor: John BURNIER
-
Publication number: 20160368902Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.Type: ApplicationFiled: August 12, 2016Publication date: December 22, 2016Applicant: SARCODE BIOSCIENCE INC.Inventors: John BURNIER, Thomas GADEK, Frederic NAUD